Skip to main content
Premium Trial:

Request an Annual Quote

Applied DNA Sciences Linea COVID-19 Selective Genomic Surveillance Mutation Panel

Applied DNA Sciences has launched the Linea COVID-19 Selective Genomic Surveillance Mutation Panel (SGS Panel) to enhance the utility of next-generation sequencing resources in the US to better track SARS-CoV-2 variants of concern at the local, state, and federal levels. The research-use-only SGS Panel uses a matrix of proprietary qPCR assays that target salient mutations that characterize relevant identified variants of concern to narrow the selection of positive samples worth subjecting to NGS analysis, the Stony Brook, New York-based company said. Applied DNA Sciences will offer the SGS panel in 100 reaction kits. It is also planning to offer additional RUO services that include NGS sequencing of entire viral genomes. The firm is targeting the sequencing of 100 SARS-CoV-2 viromes per day with a capacity for twice that number.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.